51
|
Dupont R, Bérard E, Puisset F, Comont T, Delord JP, Guimbaud R, Meyer N, Mazieres J, Alric L. The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non-small-cell lung cancer: a real-life retrospective study. Oncoimmunology 2019; 9:1682383. [PMID: 32002292 PMCID: PMC6959447 DOI: 10.1080/2162402x.2019.1682383] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2019] [Revised: 10/14/2019] [Accepted: 10/14/2019] [Indexed: 12/26/2022] Open
Abstract
Background: Nivolumab and pembrolizumab, two PD1 inhibitors, trigger immune-related adverse events in approximately 50% of patients. Our objective was to determine whether these immune-related adverse events are associated with patient outcomes. Patients and Methods: Retrospective cohort study, realized at the Institut Universitaire du Cancer de Toulouse, of all the patients treated with nivolumab or pembrolizumab off clinical trials. We included patients (i) diagnosed with unresectable stage III or stage IV melanoma or with recurrent stage IIIB or stage IV non-small cell lung cancer (ii) on nivolumab 3mg/kg or pembrolizumab 2mg/kg every 2 or 3 weeks respectively. Results: Of the 311 patients included (of 641 eligible subjects), 120 (38.6%) had melanoma and 191 (61.4%) had non-small cell lung cancer; 241 (77.5%) were treated with nivolumab with a median follow-up of 24 months (20-29). We observed 166 immune-related adverse events in 116 (37.3%) patients, categorized as "early" (onset before 12 weeks in melanoma and before 8 weeks in lung cancer) in 63 (54.3%) patients. Early and late adverse events were significantly associated with an increase in overall survival: adjusted hazard ratio 0.58 [0.41-0.84] (p = .003) and 0.28 [0.16-0.50] (p < .001) respectively. The overall response rate was significantly increased in patients with an immune-related adverse event (53.9% vs 12.9%, p < .001) Conclusions: This study validates the association between immune-related adverse events and anti-PD1 efficacy in real-life, especially if these events are delayed. Our results, along with further studies on the place of immunosuppressive drugs in the therapeutic strategy, could improve the management of these adverse events.
Collapse
|
52
|
Comont T, Belliere J, Sibaud V, Alric L, Meyer N, Mazières J, Caron P, Acket B, Michot JM, Beyne-Rauzy O, Lambotte O. [Immune-related adverse events after immune checkpoints inhibitors in 2019: An update]. Rev Med Interne 2019; 41:37-45. [PMID: 31668882 DOI: 10.1016/j.revmed.2019.09.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2019] [Revised: 09/23/2019] [Accepted: 09/26/2019] [Indexed: 12/11/2022]
Abstract
Use of checkpoint inhibitors to treat cancer was one of the most important revolution these last years and an increasing number of new types of tumors is currently under investigation with these new treatments. However, immune-related adverse events associated with these agents frequently affect various organs, mimicking auto-immune or inflammatory diseases. Some of these effects can be severe, often requiring hospitalization and specialized treatment (immunosuppression). Most known agents are ipilimumab (anti-CTLA-4 antibody) nivolumab and pembrolizumab (anti-PD-1 antibodies). New molecules are now approved or in development as anti-PD-L1 antibodies, anti-LAG-3 or anti-TIM-3 antibodies, increasing the probability and new description of immune-related adverse events. With his experience in auto-immune diseases, the immunologist/internal medicine specialist has an important role in the management of these toxicities. The goal of this review is to focus on the incidence, diagnostic assessment and recommended management of the most relevant immune-related adverse events.
Collapse
|
53
|
Saiag P, Mortier L, Dutriaux C, Benmahammed L, Morsli O, Train C, Spampinato A, Leccia M, Meyer N, Grob J. Outcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz255.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
54
|
Grob J, Gonzalez Mendoza R, Basset-Seguin N, Vornicova O, Schachter J, Joshi A, Meyer N, Grange F, Piulats J, Bauman J, Zhang P, Gumuscu B, Swaby R, Hughes B. Pembrolizumab for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC): Efficacy and safety results from the phase II KEYNOTE-629 study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.069] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
55
|
Modesto A, Dalmasso C, Chaltiel L, Pagès C, Boulinguez S, Sibaud V, Chira C, Latorzeff I, Lubrano V, Moyal É, Meyer N. Le traitement local intracrânien des métastases cérébrales de mélanome allonge la survie globale des patients pris en charge par immunothérapie ou anti-Braf. Cancer Radiother 2019. [DOI: 10.1016/j.canrad.2019.07.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
56
|
Desrousseaux J, Cabarrou B, Modesto A, Rives M, Parent L, Brun T, Tournier A, Arnaud F, Meyer N, Sibaud V, Pages C, Boulinguez S, Gangloff D, Chira C. Electronic Brachytherapy for Skin Carcinomas of the Face : Practical Considerations from a Retrospective Series of 53 Lesions. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
57
|
Hayward MW, Callen A, Allen BL, Ballard G, Broekhuis F, Bugir C, Clarke RH, Clulow J, Clulow S, Daltry JC, Davies-Mostert HT, Fleming PJS, Griffin AS, Howell LG, Kerley GIH, Klop-Toker K, Legge S, Major T, Meyer N, Montgomery RA, Moseby K, Parker DM, Périquet S, Read J, Scanlon RJ, Seeto R, Shuttleworth C, Somers MJ, Tamessar CT, Tuft K, Upton R, Valenzuela-Molina M, Wayne A, Witt RR, Wüster W. Deconstructing compassionate conservation. CONSERVATION BIOLOGY : THE JOURNAL OF THE SOCIETY FOR CONSERVATION BIOLOGY 2019; 33:760-768. [PMID: 31206825 DOI: 10.1111/cobi.13366] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/03/2019] [Accepted: 05/19/2019] [Indexed: 06/09/2023]
Abstract
Compassionate conservation focuses on 4 tenets: first, do no harm; individuals matter; inclusivity of individual animals; and peaceful coexistence between humans and animals. Recently, compassionate conservation has been promoted as an alternative to conventional conservation philosophy. We believe examples presented by compassionate conservationists are deliberately or arbitrarily chosen to focus on mammals; inherently not compassionate; and offer ineffective conservation solutions. Compassionate conservation arbitrarily focuses on charismatic species, notably large predators and megaherbivores. The philosophy is not compassionate when it leaves invasive predators in the environment to cause harm to vastly more individuals of native species or uses the fear of harm by apex predators to terrorize mesopredators. Hindering the control of exotic species (megafauna, predators) in situ will not improve the conservation condition of the majority of biodiversity. The positions taken by so-called compassionate conservationists on particular species and on conservation actions could be extended to hinder other forms of conservation, including translocations, conservation fencing, and fertility control. Animal welfare is incredibly important to conservation, but ironically compassionate conservation does not offer the best welfare outcomes to animals and is often ineffective in achieving conservation goals. Consequently, compassionate conservation may threaten public and governmental support for conservation because of the limited understanding of conservation problems by the general public.
Collapse
|
58
|
Meyer N, Xu H, Wax JF. The role of chemical order in the temperature and composition dependence of the viscosity of liquid alloys. J Chem Phys 2019; 150:174502. [PMID: 31067875 DOI: 10.1063/1.5092694] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
The influence of the chemical order on the viscosity of liquid alloys is investigated by numerical simulation of molecular dynamics. The temperature and composition dependence is discussed in the case of two contrasting alloys: K-Cs and Li-Bi. These two mixtures have different chemical orders, the first one being random and the second one having strong heterocoordination tendencies. In the case of K-Cs, the behavior of the mixture vs temperature is similar to a pure system and its viscosity varies monotonically with the composition. It is not the case for Li-Bi due to its marked chemical order and the heterocoordination tendency is accompanied by a maximum of the viscosity of the mixture when the composition is changed. For the first time, estimates of the temperature dependence of the viscosity of three representative Li-Bi alloys are given.
Collapse
|
59
|
Ferreira D, Vivot A, Meyer N. Méthodes bayésiennes dans les essais contrôlés randomisés de phase III : une revue systématique. Rev Epidemiol Sante Publique 2019. [DOI: 10.1016/j.respe.2019.03.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
60
|
Ferreira D, Barthoulot M, Pottecher J, Diemunsch P, Meyer N. Une checklist pour les essais cliniques analysés en Bayésien. Rev Epidemiol Sante Publique 2019. [DOI: 10.1016/j.respe.2019.03.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
61
|
Modesto A, Chira C, Sol JC, Lubrano V, Boulinguez S, Pagès C, Sibaud V, Gomez-Roca C, Moyal É, Meyer N. Prise en charge des patients atteints de métastases cérébrales de mélanome. Cancer Radiother 2019. [DOI: 10.1016/j.canrad.2019.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
62
|
Modesto A, Chira C, Sol JC, Lubrano V, Boulinguez S, Pagès C, Sibaud V, Gomez-Roca C, Moyal É, Meyer N. Prise en charge des patients atteints de métastases cérébrales de mélanome. Cancer Radiother 2019; 23:147-150. [DOI: 10.1016/j.canrad.2018.05.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2018] [Revised: 05/15/2018] [Accepted: 05/17/2018] [Indexed: 11/29/2022]
|
63
|
Modesto A, Chira C, Sol JC, Lubrano V, Boulinguez S, Pagès C, Sibaud V, Gomez-Roca C, Moyal É, Meyer N. Prise en charge des patients atteints de métastases cérébrales de mélanome. Cancer Radiother 2019. [DOI: 10.1016/j.canrad.2019.03.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
64
|
Santamaría C, Abud J, Porporato M, Meyer N, Zenclussen A, Kass L, Rodríguez H. The UV filter benzophenone 3, alters early follicular assembly in rat whole ovary cultures. Toxicol Lett 2019; 303:48-54. [DOI: 10.1016/j.toxlet.2018.12.016] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2018] [Revised: 12/20/2018] [Accepted: 12/28/2018] [Indexed: 10/27/2022]
|
65
|
Borne E, Meyer N, Rybarczyck-Vigouret MC, Blanchard O, Lombard M, Lang PO, Vogel T, Michel B. Prescriptions potentiellement inappropriées de statines chez les sujets âgés : analyse à partir des bases de données de l’Assurance maladie. Rev Epidemiol Sante Publique 2019. [DOI: 10.1016/j.respe.2018.11.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
66
|
Dagrenat C, Von Hunolstein J, Thebaud L, Marchandot B, Messas N, Greciano S, Tuzin N, Meyer N, Trinh A, Jesel L, Ohlmann P, Morel O. Value of cardiac biomarkers in the early diagnosis of Takotsubo syndrome. ARCHIVES OF CARDIOVASCULAR DISEASES SUPPLEMENTS 2019. [DOI: 10.1016/j.acvdsp.2018.10.318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
67
|
Dupont R, Berard E, Puisset F, Comont T, Guimbaud R, Meyer N, Mazieres J, Alric L. Colite ou hépatite immunologiques au cours du traitement par nivolumab et du pembrolizumab pour un mélanome ou un cancer bronchique : un facteur de bon pronostic. Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.10.187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
68
|
Dupont R, Berard E, Puisset F, Fort M, Comont T, Guimbaud R, Meyer N, Mazieres J, Alric L. Facteurs prédictifs de survenue des effets indésirables immunologiques au cours du traitement du mélanome et du cancer bronchique par inhibiteurs de check point. Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.10.338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
69
|
Gerard E, Dupuis F, Lamant L, Torossian N, Chaltiel L, Filleron T, Beylot-Barry M, Dutriaux C, Prey S, Gros A, Jullie ML, Meyer N, Vergier B. Évaluation des critères cliniques, pathologiques et moléculaires prédictifs de réponse à l’immunothérapie anti-PD1 dans le mélanome métastatique : analyse rétrospective de 70 patients. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
70
|
Varey E, Thomas L, Dalle S, Lesimple T, Lacour JP, Guillot B, Mortier L, Leccia MT, Skowron F, Celerier P, Meyer N, Combemale P, Crickx B, Dutriaux C, Dalac-Rat S, Khammari A, Lebbé C, Dréno B. Développement des nouveaux traitements en situation adjuvante du mélanome : données épidémiologiques de la base RIC-Mel. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.499] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
71
|
Fradet M, Bulai-Livideanu C, Lamant L, Tournier E, Laurent C, Apoil PA, Meyer N, Sibaud V. Deux cas d’urticaire pigmentaire radio-induite révélant une mastocytose systémique. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
72
|
Chaplain L, Blom A, Samimi M, Guillot B, Jouary T, Grob JJ, Meyer N, Zehou O, Combemale P, Lebbé C, Jeudy G, Grange F, Lacour P, Dinulescu M, Granel Brocard F, Beneton N, Aubin F, Bens G, De Quatrebarbes J, Steff M, Arnault JP, Le Corre Y, Stefan A, D’Incan M, Kramkimel N, Leccia MT, Thomas Beaulieu D, Maubec E, Robert C, Dreno B, Wierzbicka-Hainaut E, Lenormand C, Saiag P, Mortier L. Carcinome de Merkel : état des lieux du réseau CARADERM. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
73
|
Delyon J, Porcher R, Battistella M, Meyer N, Adamski H, Bertucci F, Guillot B, Jouary T, Leccia MT, Dalac S, Mortier L, Vicaut E, Pedeutour F, Mourah S, Lebbe C. Essai de phase II multicentrique évaluant le pazopanib dans le traitement du dermatofibrosarcome non opérable ou récidivant. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
74
|
Raynal M, Lheure C, Seta V, Chanal J, Franck N, Sarah G, Dupin N, Aractingi S, Meyer N, Kramkimel N. Traitement de mélanomes métastatiques avec mutation de NRAS par inhibiteur de MEK après échec de l’immunothérapie. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
75
|
Deilhes F, Pagès C, Guillemette S, Sibaud V, Regnault MM, Tournier E, Meyer N. Xeroderma pigmentosum : un nouveau cas d’efficacité des anticorps anti-PD1 dans le traitement d’un mélanome non résécable et de multiples proliférations épithéliales cutanées. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|